Menu

Federal Contractor Misconduct Database (FCMD)

The federal government routinely awards contracts to companies with histories of misconduct, including contract fraud and other violations. POGO believes that providing this website will help to improve contracting decisions and increase public knowledge of how the government spends billions of taxpayer dollars each year. Read more…

Rapamune Off-Label Promotion – Multi-State Settlement

Pfizer agreed to pay $35 million to 41 states and the District of Columbia to resolve allegations that Wyeth Pharmaceuticals (acquired by Pfizer in 2009) promoted off-label uses for its Rapamune kidney transplant drug. Wyeth allegedly engaged in off-label marketing, promoting the drug for uses that were not approved by the Food and Drug Administration. Wyeth also allegedly violated state consumer protection laws by misrepresenting Rapamune’s uses and benefits through an orchestrated campaign of promotional talks by Wyeth-retained doctors, misleading presentations of data, and company-funded studies at hospitals and transplant centers designed to encourage off-label uses of Rapamune. In July 2013, Wyeth paid $490.9 million and pleaded guilty in a legal matter involving similar allegations. (see Pfizer, Inc. instance, “Sandler et al. v. Wyeth Pharmaceuticals”).

Misconduct Type
Health
Enforcement Agency
State/Local
Contracting Party
None
Court Type
Civil
Disposition
Settlement
Date of Settlement Announcement
8/6/2014
Contractors Involved Penalty
Total
Pfizer, Inc. $35,000,000
Further Information Released
NY Attorney General Press Release 8/6/2014
Settlement Agreement 8/6/2014

See also:

Federal Contractor Misconduct Database